You can find the University's latest news, events and blogs at

Breakthrough in brain tumour research

Glioblastoma, one of the most aggressive forms of brain tumour, which kills thousands of patients within a year. CREDIT: Alison Howarth, therapeutics team at the Brain Tumour Research’s centre of excellence, University of Portsmouth

Glioblastoma, one of the most aggressive forms of brain tumour, which kills thousands of patients within a year. CREDIT: Alison Howarth, therapeutics team at the Brain Tumour Research’s centre of excellence, University of Portsmouth

A potentially ground-breaking scientific breakthrough with far-reaching consequences for future treatments of brain tumours is to be revealed at an international research meeting in Poland today.

Professor Geoff Pilkington and Dr Richard Hill, from the Brain Tumour Research Centre of Excellence at the University of Portsmouth, will present their research findings at the conference “Brain Tumours 2016 – From Biology to Therapy”.  Their group has been collaborating with Innovate Pharmaceuticals who have developed a novel formulation “IP1867B”, combining reformulated aspirin with two additional ingredients, into a soluble form.  Developing a true liquid aspirin has long been a scientific goal, as “soluble” aspirins currently on the market are not completely soluble and still contain grains that cause gastric side effects.

Most significantly for patients with brain tumours, this new formulation significantly increases the ability of drugs to cross the blood brain barrier.  This membrane serves to protect the brain but also blocks many conventional cancer drugs from reaching brain tumours.  This research suggests that Innovate Pharmaceutical’s IP1867B could be highly effective against glioblastoma (GBM), one of the most aggressive forms of the disease, which kills thousands of patients within a year.

The breakthrough came in laboratory tests on cancer cells from adults and children with brain tumours. In all the variations of drugs tested, including separating out the three key components of IP1867B, it was ten times more effective than any combination of other currently used drugs.

All three ingredients, which are already approved for use in the clinic, have been shown to kill tumour cells without having an effect on normal brain cells.  Although the drug will now be further developed in pre-clinical models, more research will be needed before we know whether it will be suitable for patients in clinical trials.

Sue Farrington Smith, Chief Executive of Brain Tumour Research, said: “This is a potential game-changer for research into brain tumours and clearly shows what sustainable research is able to achieve.  It is science like this that will enable us to eventually find a cure for this devastating disease which kills more children and adults under the age of 40 than any other cancer.”

6 total comments on this postSubmit yours
  1. My dear friend has glio-blastoma. Are there any trials she can go on re the aspirin trials which I read about in the Daily Mail? Or is the liquid aspirin available from a private consultant. Please reply. I,m trying all avenues. Many thanks, Berenice Stansfield

    • While I don’t believe we are running trials here, I have asked the researcher to contact you to advise where there might be trials taking place.

  2. My husband has a glioblastoma and I am researching all possible treatments. He has finished surgery, radio/chemo and 6 rounds of chemo but I feel helpless that there are no other treatments available. Please let me know of any trials or way of accessing the aspirin combination. We live quite near to Portsmouth.

  3. Dear sir or madam my nephew has grade 4 brain tumour he is 38 could you please tell me if there is any trials he could attend yours Richard

  4. Re: BRAIN CANCER (GBM stage 4!) From StatNews is how I got here and coincidentally: Anybody with GBM should consult DIRECTLY with the best: renowned UCLA’s GBM trials underseen by Dr. Linda Liau as seen here: 1) with special reference: Even further along is a vaccine that also targets molecules on a patient’s unique glioblastoma but in a somewhat different way from the Dana-Farber approach. Manufacturer Northwest Biotherapeutics has recruited 331 glioblastoma patients into a late-stage clinical trial, and at this year’s meeting of the American Society of Clinical Oncology reported that 40 percent of patients treated with “DCVax-L” were still alive at 35 months, compared with 15 percent of patients receiving standard care; 24 percent of patients who got the vaccine were alive after four years, compared with 8 percent otherwise.”
    2) in which Dr. Linda Liau is interviewed: her mother died of GBM and she dedicated HER LIFE to become a Dr. and one of the world’s leading experts NOW in GBM: a Ph3 DC VAX L trial is closed with results on the near horizon.
    Obviously there are a number of specialists one can deal with: LOTS of published commentary by some are BIASED based on WHO is sponsoring their hospital’s clinics (ie. DanaFarber’s Reardon w/ CLDX!)
    ALSO consider what CBS 60 mins have profiled since 2015 with Duke Univ trial with

    Consider the fact that DCVAX L has treated a few thousand patients ALL safely versus Duke’s Poilo Vaccine: less than 100 to date.

    Best of luck: TIME IS OF THE ESSENSE: some GBM patients have died within 5 mos!

    Do believe that the above is OBJECTIVE: do your own due diligence!

10 total pingbacks on this post

UoP News © 2020 All Rights Reserved